DNA molecular electrostatic potential: novel perspectives for the mechanism of action of anticancer drugs involving electron transfer and oxidative stressKOVACIC, Peter; WAKELIN, Laurence Pg.Anti-cancer drug design. 2001, Vol 16, Num 4-5, pp 175-184, issn 0266-9536Article

Synthesis and antitumor activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinonesANDREANI, Aldo; GRANAIOLA, Massimiliano; LEONI, Alberto et al.Anti-cancer drug design. 2001, Vol 16, Num 2-3, pp 167-174, issn 0266-9536Article

PKC412-a protein kinase inhibitor with a broad therapeutic potential : Protein kinaseFABBRO, D; RUETZ, S; BODIS, S et al.Anti-cancer drug design. 2000, Vol 15, Num 1, pp 17-28, issn 0266-9536Article

Synthesis of new homochiral bispyrrolidines as potential DNA cross-linking antitumour agentsANDERSON, F. M; O'HARE, C. C; HARTLEY, J. A et al.Anti-cancer drug design. 2000, Vol 15, Num 2, pp 119-126, issn 0266-9536Article

UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds : a new generation of anti-cancer agents for the new century ? : Protein kinaseAKINAGA, S; SUGIYAMA, K; AKIYAMA, T et al.Anti-cancer drug design. 2000, Vol 15, Num 1, pp 43-52, issn 0266-9536Article

Antineoplastic agents 453. Synthesis of pancratistatin prodrugsPETTIT, George R; ORR, Brian; DUCKI, Sylvie et al.Anti-cancer drug design. 2000, Vol 15, Num 6, pp 389-395, issn 0266-9536Article

Design, synthesis and antitumor cytotoxicity of novel bis-benzimidazolesSINGH, Ashok K; LOWN, J. William.Anti-cancer drug design. 2000, Vol 15, Num 4, pp 265-275, issn 0266-9536Article

Role of crown-like side chains in the biological activity of substituted-phenoxazone drugsKARAWAJEW, Leonid; GLIBIN, Eugene N; MALEEV, Vladimir Ya et al.Anti-cancer drug design. 2000, Vol 15, Num 5, pp 331-338, issn 0266-9536Article

Synthesis and antiproliferative activity of unsaturated quinoline derivativesMONTGOMERY, Gerard J; MCKEOWN, Paul; MCGOWN, Alan T et al.Anti-cancer drug design. 2000, Vol 15, Num 3, pp 171-181, issn 0266-9536Article

Synthesis and cytotoxic activity of carboxamide derivatives of benzimidazo[2,1-a]isoquinoline and pyrido[3', 2':4,5]imidazo[2,1-a]isoquinolineDEADY, Leslie W; RODEMANN, Thomas; FINLAY, Graeme J et al.Anti-cancer drug design. 2000, Vol 15, Num 5, pp 339-346, issn 0266-9536Article

Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cellsENGMAN, Lars; KANDA, Takahiro; GALLEGOS, Alfred et al.Anti-cancer drug design. 2000, Vol 15, Num 5, pp 323-330, issn 0266-9536Article

A rational design of bioactive taxanes with side chains situated elsewhere than on C-13JIAN HUI WU; ZAMIR, L. O.Anti-cancer drug design. 2000, Vol 15, Num 1, pp 73-78, issn 0266-9536Article

Biological properties of 5,11-dimethyl-6H-pyrido[3,2-b]carbazoles : a new class of potent antitumour drugsMOINET-HEDIN, V; TABKA, T; POULAIN, L et al.Anti-cancer drug design. 2000, Vol 15, Num 2, pp 109-118, issn 0266-9536Article

Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cellsRAPPA, G; MURREN, J. R; JOHNSON, L.-M et al.Anti-cancer drug design. 2000, Vol 15, Num 2, pp 127-134, issn 0266-9536Article

Pyrimido[4,5,6-kl]acridines. Synthesis, in vitro cytotoxicity and structure-activity relationshipsANTONINI, I; POLUCCI, P; MARTELLI, S et al.Anti-cancer drug design. 1999, Vol 14, Num 5, pp 451-459, issn 0266-9536Article

Antitumour imidazotetrazines. Part 37. Conjugation of the DNA major-groove alkylating imidazotetrazine mitozolomide to peptide motifs recognizing the minor grooveARROWSMITH, J; MISSAILIDIS, S; STEVENS, M. F. G et al.Anti-cancer drug design. 1999, Vol 14, Num 3, pp 205-217, issn 0266-9536Article

Bis-benzimidazole anticancer agents : targeting human tumour helicasesSODERLIND, K.-J; GORODETSKY, B; SINGH, A. K et al.Anti-cancer drug design. 1999, Vol 14, Num 1, pp 19-36, issn 0266-9536Article

Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphomaOSADA, M; ISHIOKA, C; ICHINOHASAMA, R et al.Anti-cancer drug design. 1999, Vol 14, Num 2, pp 107-114, issn 0266-9536Article

Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivativesBAILLY, C; DASSONNEVILLE, L; CARRASCO, C et al.Anti-cancer drug design. 1999, Vol 14, Num 1, pp 47-60, issn 0266-9536Article

Sequence selectivity, cross-linking efficiency and cytotoxicity of DNA-targeted 4-anilinoquinoline aniline mustardsMCCLEAN, S; COSTELLOE, C; DENNY, W. A et al.Anti-cancer drug design. 1999, Vol 14, Num 3, pp 187-204, issn 0266-9536Article

Accurate determination of quadruplex binding affinity and potency of G-quadruplex-interactive telomerase inhibitors by use of a telomerase extension assay requires varying the primer concentrationCATHERS, B. E; DAEKYU SUN; HURLEY, L. H et al.Anti-cancer drug design. 1999, Vol 14, Num 4, pp 367-372, issn 0266-9536Article

Antitumor activity of a PKC-α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude miceGEIGER, T; MÜLLER, M; DEAN, N. M et al.Anti-cancer drug design. 1998, Vol 13, Num 1, pp 35-45, issn 0266-9536Article

Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cellsDISTEFANO, M; SCAMBIA, G; FERLINI, C et al.Anti-cancer drug design. 1998, Vol 13, Num 5, pp 489-499, issn 0266-9536Article

Antitumour polycyclic acridines. Part 2. Physicochemical studies on the interactions between DNA and novel polycyclic acridine derivativesGIMENEZ-ARNAU, E; MISSAILIDIS, S; STEVENS, M. F. G et al.Anti-cancer drug design. 1998, Vol 13, Num 2, pp 125-143, issn 0266-9536Article

Antitumour polycyclic acridines. Part 4. Physico-chemical studies on the interactions between DNA and novel tetracyclic acridine derivativesGIMENEZ-ARNAU, E; MISSAILIDIS, S; STEVENS, M. F. G et al.Anti-cancer drug design. 1998, Vol 13, Num 5, pp 431-451, issn 0266-9536Article